GeneTex
United States (US)

VEGF antibody [VG1]

Anti-VEGF antibody [VG1] used in IHC (Paraffin sections) (IHC-P). GTX21316
Anti-VEGF antibody [VG1] used in IHC (Paraffin sections) (IHC-P). GTX21316

Cat No. GTX21316

Reference 12
Host Mouse
Clonality Monoclonal
Clone Name VG1
Isotype IgG1
Application WB, ICC/IF, IHC-P, IHC-Fr, ELISA
Reactivity Human, Mouse, Rat
See all VEGF products
APPLICATION

Application Note

IHC-P: 1:25 - 1:50 in ABC method. Suggested incubation period of 30 minutes at room temperature. . High temperature treatment of formalin-fixed tissue sections using 1mM EDTA, pH 8.0 must be performed prior to the immunostaining. Not yet tested in other applications. Optimal ilutions/concentrations should be determined by the end user.

Positive Control

Astrocytoma

Specificity/Sensitivity

This antibody is specific to a cluster of proteins between 19-22kD (reduced). VEGF is a homodimeric disulfide-linked glycoprotein involved in angiogenesis, which promotes tumor progression and metastasis. It exhibits potent mitogenic and permeability inducing properties specific for the vascular endothelium.
PROPERTIES

Form

Liquid

Buffer

PBS with 1% BSA and 0.05% sodium azide in it.

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.

Antigen Species

Human

Immunogen

Recombinant VEGF protein.

Purification

Protein G purified

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

VEGFA, VPF, 125853, 7422, P15692, MGC70609, VEGF, MVCD1

Cellular Localization

Secreted

Background

VEGF (Vascular Endothelial Growth Factor) is a homodimeric, disulfide-linked glycoprotein involved in angiogenesis which promotes tumor progression and metastasis. It exhibits potent mitogenic and permeability inducing properties specific for the vascular endothelium. Of the four isoforms of VEGF, the smaller two, VEGF 165 and VEGF 121, are secreted proteins and act as diffusible agents, whereas the larger two (VEGF 189 and VEGF 206) remain cell associated.

Research Area

DATA IMAGES
Anti-VEGF antibody [VG1] used in IHC (Paraffin sections) (IHC-P). GTX21316

GTX21316 IHC-P Image

IHC Image using GTX21316 - Detection of VEGF by IHC in Human Angiosarcoma
Anti-VEGF antibody [VG1] used in IHC (Paraffin sections) (IHC-P). GTX21316

GTX21316 IHC-P Image

IHC-P analysis of human kidney using VEGF antibody [VG1].
REFERENCE

Application Reference

Lennikov A et al. Angiogenesis 2018; (Epub ahead of print) Selective IKK2 inhibitor IMD0354 disrupts NF-κB signaling to suppress corneal inflammation and angiogenesis.
Application : ICC/IF, IHC-P
Reactivity : Human
Mirabelli P et al. Sci Rep 2017; 7 (1) : 7616 Genome-wide expression differences in anti-Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea.
Application : WB, IHC-P
Reactivity : Rat
Chiang CH et al. Am J Cancer Res 2016; 6 (8) : 1785-98 MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7.
Application : WB
Reactivity : Human
Mukwaya A et al. Sci Rep 2016; 6 : 32137 Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis.
Application : IHC-P
Reactivity : Rat

Clone Reference

Bai X et al. PLoS One 2014; 9 (4):e96117 Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes.
Application : IHC-Fr
Reactivity : Rat
Show More +
Submit a Reference
Application Reference
Lennikov A et al. Angiogenesis 2018; (Epub ahead of print) Selective IKK2 inhibitor IMD0354 disrupts NF-κB signaling to suppress corneal inflammation and angiogenesis.
Application : ICC/IF, IHC-P
Reactivity : Human
Mirabelli P et al. Sci Rep 2017; 7 (1):7616 Genome-wide expression differences in anti-Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea.
Application : WB, IHC-P
Reactivity : Rat
Chiang CH et al. Am J Cancer Res 2016; 6 (8):1785-98 MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7.
Application : WB
Reactivity : Human
Mukwaya A et al. Sci Rep 2016; 6:32137 Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis.
Application : IHC-P
Reactivity : Rat
Clone Reference
Duscher D et al. Sci Rep 2014; 4:7144 Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells.
Application : IHC-Fr
Reactivity : Mouse
Bai X et al. PLoS One 2014; 9 (4):e96117 Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes.
Application : IHC-Fr
Reactivity : Rat
Zhao M et al. Exp Eye Res 2011; 93 (6):921-6 Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy.
Application : WB, IHC-P
Reactivity : Mouse
Long J et al. J Biol Chem 2010; 285 (30):23457-65 Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions.
Application : ICC/IF
Reactivity : Mouse
Marengo B et al. Oncol Rep 2010; 23 (5):1241-6 DNA oxidative damage of neoplastic rat liver lesions.
Application : IHC-Fr
Reactivity : Rat
van der Loos CM et al. J Histochem Cytochem 2010; 58 (2):109-18 Anti-human vascular endothelial growth factor (VEGF) antibody selection for immunohistochemical staining of proliferating blood vessels.
Application : WB
Reactivity : Human
De Francesco F et al. PLoS One 2009; 4 (8):e6537 Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries.
Application : ICC/IF
Reactivity : Human
Turley H et al. J Pathol 1998; 186 (3):313-8 Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1.
Application : ELISA
Reactivity : Human
Package List Price ($)
$ 319